L-R Zhu1, J Li2, P Chen1, Q Jiang3, X-P Tang1. 1. Department of Pulmonary Medicine, Affiliated Hospital of Jiangsu University, 438 North Jiefang Street, Zhenjiang, 212001, China. 2. Department of Pulmonary Medicine, Affiliated Hospital of Jiangsu University, 438 North Jiefang Street, Zhenjiang, 212001, China. lijian541226@163.com. 3. Center of Experimental Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Abstract
PURPOSE: Elevated plasma fibrinogen and D-dimer levels indicate activation of hemostasis and fibrinolysis, and this activation is required for tumor angiogenesis, metastasis, and invasion. Previous studies demonstrated that the plasma fibrinogen and D-dimer levels correlate with patient's prognosis in several solid tumors. The aim of this study is to examine the relationship between plasma fibrinogen and D-dimer levels before and during chemotherapy and treatment response and survival in patients with small cell lung cancer (SCLC). METHODS: Plasma fibrinogen and D-dimer levels before and during chemotherapy were prospectively measured in 74 SCLC patients who received first-line therapy. The results were analyzed for correlation between fibrinogen and D-dimer levels and treatment response, as well as progressive-free survival (PFS) and overall survival (OS). RESULTS: The levels of fibrinogen and D-dimer in SCLC patients before (C0) and after two cycles (C2) of chemotherapy were significantly higher than those in controls. Fibrinogen and D-dimer levels decreased during chemotherapy, and changes in fibrinogen and D-dimer levels between at C0 and at C2 were associated with treatment response. No matter which disease stage, patients with fibrinogen or D-dimer positivities at C0 and C2 time points had worse PFS and OS than those with fibrinogen or D-dimer negativities. Multivariate analyses revealed that fibrinogen and D-dimer positivities after two chemotherapy cycles were independently unfavorable factors for PFS and OS. CONCLUSION: Fibrinogen and D-dimer levels after two cycles of chemotherapy are predictors for response on chemotherapy and prognosis in SCLC patients.
PURPOSE: Elevated plasma fibrinogen and D-dimer levels indicate activation of hemostasis and fibrinolysis, and this activation is required for tumor angiogenesis, metastasis, and invasion. Previous studies demonstrated that the plasma fibrinogen and D-dimer levels correlate with patient's prognosis in several solid tumors. The aim of this study is to examine the relationship between plasma fibrinogen and D-dimer levels before and during chemotherapy and treatment response and survival in patients with small cell lung cancer (SCLC). METHODS: Plasma fibrinogen and D-dimer levels before and during chemotherapy were prospectively measured in 74 SCLCpatients who received first-line therapy. The results were analyzed for correlation between fibrinogen and D-dimer levels and treatment response, as well as progressive-free survival (PFS) and overall survival (OS). RESULTS: The levels of fibrinogen and D-dimer in SCLCpatients before (C0) and after two cycles (C2) of chemotherapy were significantly higher than those in controls. Fibrinogen and D-dimer levels decreased during chemotherapy, and changes in fibrinogen and D-dimer levels between at C0 and at C2 were associated with treatment response. No matter which disease stage, patients with fibrinogen or D-dimer positivities at C0 and C2 time points had worse PFS and OS than those with fibrinogen or D-dimer negativities. Multivariate analyses revealed that fibrinogen and D-dimer positivities after two chemotherapy cycles were independently unfavorable factors for PFS and OS. CONCLUSION:Fibrinogen and D-dimer levels after two cycles of chemotherapy are predictors for response on chemotherapy and prognosis in SCLCpatients.
Entities:
Keywords:
Chemotherapy; D-dimer; Fibrinogen; Prognosis; Response; Small cell lung cancer
Authors: Joseph S Palumbo; Jill M Potter; Lisa S Kaplan; Kathryn Talmage; David G Jackson; Jay L Degen Journal: Cancer Res Date: 2002-12-01 Impact factor: 12.701
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Jae Hong Im; Weili Fu; Hui Wang; Sujata K Bhatia; Daniel A Hammer; M Anna Kowalska; Ruth J Muschel Journal: Cancer Res Date: 2004-12-01 Impact factor: 12.701
Authors: Patrick C Ma; Lawrence Blaszkowsky; Ajit Bharti; Andras Ladanyi; Stine-Kathrein Kraeft; Adam Bruno; Arthur T Skarin; Lan Bo Chen; Ravi Salgia Journal: Anticancer Res Date: 2003 Jan-Feb Impact factor: 2.480
Authors: Joseph D Khoury; Dorothy M Adcock; Fanny Chan; James T Symanowski; Stefan Tiefenbacher; Oscar Goodman; Lazara Paz; Yupo Ma; David C Ward; Nicholas J Vogelzang; Louis M Fink Journal: Am J Clin Pathol Date: 2010-12 Impact factor: 2.493
Authors: Grzegorz Królczyk; Michał Ząbczyk; Grzegorz Czyżewicz; Krzysztof Plens; Shannon Prior; Saulius Butenas; Anetta Undas Journal: J Thorac Dis Date: 2018-12 Impact factor: 2.895
Authors: Fangtao Yin; Hongyu Zhu; Songlin Hong; Chen Sun; Jie Wang; Mengting Sun; Lin Xu; Xiaoxiao Wang; Rong Yin Journal: Ann Transl Med Date: 2021-04